

## Q-linea receives letter of intent to evaluate and potential commercialization of Podler

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received a Letter of Intent (LOI) for the evaluation and a possible commercialization partnership for Podler with a large market leading company.

The Podler technology is currently under development within Q-linea and could enable a significant improvement in blood culturing for patients with blood infections, of which sepsis is the most severe condition. Podler is a handheld fully autonomous device to incubate and detect growth in blood culture bottles. The technology can make use of valuable transportation time, time which may be wasted when using traditional methods. The use of transportation time could enable much faster time to result for patients with blood infections and provide equal care to patients with severe infections.

"This is an important step in our strategy for the commercialization of the Podler technology. The traditional blood culturing market is dominated by only a few major companies, and to have early interest in evaluating Podler is of course a very positive first step. It proves the serious interest we are seeing for our technology which is very positive for our future development and long term go to market strategy for Podler," said Jonas Jarvius, CEO of Q-linea.

### For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB  
[Jonas.Jarvius@qlinea.com](mailto:Jonas.Jarvius@qlinea.com)  
+46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB  
[Anders.Lundin@qlinea.com](mailto:Anders.Lundin@qlinea.com)  
+46 (0) 70-600 15 20

### About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit [www.qlinea.com](http://www.qlinea.com).

*This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-07-06 21:40 CEST.*

## Attachments

Q-linea receives letter of intent to evaluate and potential commercialization of Podler